<DOC>
	<DOC>NCT00516893</DOC>
	<brief_summary>The primary objective of the study was to evaluate the immunogenicity of natalizumab (TysabriÂ®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with relapsing forms of multiple sclerosis (MS). The secondary objective of this study was to evaluate the safety of natalizumab high titer.</brief_summary>
	<brief_title>Natalizumab High Titer Immunogenicity and Safety</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Diagnosis of a relapsing form of MS Must fall within the therapeutic indications stated in the locally approved label for natalizumab Other protocoldefined inclusion criteria may apply Prior treatment with natalizumab Considered by investigator to be immunocompromised Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>natalizumab</keyword>
	<keyword>Tysabri</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Forms of Multiple Sclerosis</keyword>
</DOC>